News from daiichi sankyo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 14, 2019, 18:02 ET Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the outcome of the U.S. Food and Drug Administration (FDA) Oncologic...


Apr 02, 2019, 05:15 ET Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant Patients

Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver Bempedoic acid ...


Nov 19, 2018, 08:35 ET Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Daiichi Sankyo (JP: 4568.T, OTC Pink: DSNKY), based in Tokyo, Japan, focused on the pharmaceutical business, today announced that the November 15...


Nov 08, 2018, 08:35 ET Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018

Daiichi Sankyo (Japan: 4568.T, OTC: DSNKY) based in Tokyo, Japan, and focused on pharmaceutical business, today announced that Daiichi Sankyo, Senior ...


Dec 01, 2017, 07:00 ET Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization

Daiichi Sankyo Company, Ltd. (hereafter, Daiichi Sankyo) and Translational Sciences today announced that Daiichi Sankyo will return all rights to...


Aug 31, 2017, 07:00 ET Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced positive top-line results from REDUCER (an Asian, phase 3, multicenter,...


Aug 31, 2017, 07:00 ET Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108

Daiichi Sankyo Co., Ltd. (TSE: 4568), and its U.S. subsidiary, Daiichi Sankyo, Inc. announced today that the company has elected to terminate its...


Aug 01, 2017, 11:49 ET Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation

Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. announced that they have agreed to enter into a program to settle, on behalf of all...


Jun 30, 2017, 07:00 ET Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced top-line results from NEUCOURSE, a phase 3 clinical trial in patients...


Feb 17, 2017, 05:00 ET Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma

ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma (HCC) did...


Oct 09, 2016, 02:30 ET Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 Congress

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced safety and preliminary efficacy data from a phase 1 study of DS-8201a, a...


May 31, 2016, 08:30 ET Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the two-part phase 3 HER3-Lung study of patritumab will not proceed...


Mar 24, 2016, 08:00 ET Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily SAVAYSA® (edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session

Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) today announced that data from three new subgroup analyses from the phase 3 ENGAGE AF-TIMI 48 study, ...


Jun 18, 2015, 08:00 ET Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the initiation of Hokusai-VTE Cancer, a multinational study, which will...


Feb 09, 2015, 07:59 ET SAVAYSA™ (edoxaban) Now Available in U.S. Pharmacies

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that SAVAYSA™ (edoxaban), an oral, once-daily selective factor...


Feb 04, 2015, 08:00 ET Daiichi Sankyo Announces First Patients in Large-Scale, Multi-National Phase 3 Clinical Programs for Mirogabalin

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced enrollment of the first patients in large-scale, multi-national clinical...


Jan 08, 2015, 10:03 ET U.S. FDA Approves Daiichi Sankyo's Once-Daily SAVAYSA™ (edoxaban) Tablets for Reduction of Stroke Risk in Non-Valvular Atrial Fibrillation and for the Treatment of Venous Thromboembolism

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has approved SAVAYSA™...


Dec 08, 2014, 07:09 ET Daiichi Sankyo Launches New Formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA® 60 mg Tablets (JAN:...


Sep 26, 2014, 07:00 ET Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA® (edoxaban) in Japan

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it received approval from the Ministry of Health, Labour and Welfare ...


Aug 31, 2014, 08:38 ET Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care

Daiichi Sankyo and the Heart Rhythm Society today announced results from a global survey, which polled cardiologists from around the world and...


Mar 24, 2014, 07:00 ET Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of East Asian ...


Jan 07, 2014, 11:09 ET Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism

Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its...


Dec 09, 2013, 08:05 ET Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients...


Nov 19, 2013, 11:50 ET Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced results today from the phase 3 ENGAGE AF-TIMI 48 study.1 This clinical trial...


Oct 25, 2012, 07:00 ET Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has completed patient enrolment in the global Hokusai-VTE phase 3 ...